Management of clozapine-induced sialorrhoea

Sumeet Gupta(Tees, Esk and Wear Valleys NHS Foundation Trust), Udayan Khastgir(Tees, Esk and Wear Valleys NHS Foundation Trust), Matthew Croft(Tees, Esk and Wear Valleys NHS Foundation Trust), Sefat Roshny(Tees, Esk and Wear Valleys NHS Foundation Trust)
BJPsych Advances
October 10, 2019
Cited by 10Open Access
Full Text

Abstract

SUMMARY Sialorrhoea (hypersalivation) is a common adverse effect of clozapine. If severe, it can affect patients' quality of life and adherence to the treatment. Clinicians therefore need to proactively manage this effect. At present, no drugs are licensed to manage clozapine-induced sialorrhoea, although there are many off-label treatment options, with variable effectiveness. Anticholinergic medications are commonly prescribed for it, but they have limited effect and can worsen constipation. This article gives a brief overview of other practical and pharmacological management options.


Related Papers

No related papers found

Powered by citation graph analysis